Join to access to all OVN content. Join for Free
Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West

Season 1, Episode 18: Challenges Facing the Pharma Universe with Jack West


Share This Article


In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Jack West, the VP of Clinical Development at Summit Therapeutics. They discuss Jack's transition from being a practicing oncologist to working in the pharmaceutical industry, the importance of collaborations with pharma, and the challenges and rewards of working in a small pharma company. "Going into a pharma company is like riding a mechanical bull. The directions change frequently and sometimes you're not ready for them." Jack also shares his insights on leadership best practices and the top challenges facing the pharma industry. "Having well-defined roles and a clear value is important in leadership." The episode concludes with a discussion on Summit Therapeutics' recent positive press releases and Jack's social media presence.

📗 Takeaways:

🤝Collaborations with pharma can be instrumental in making the leap from clinical practice to the pharmaceutical industry.

💹Transitioning from clinical practice to pharma requires a willingness to adapt to new priorities and challenges.

🕴Leadership in the pharmaceutical industry requires well-defined roles, clear value, and a culture of open communication and dissent.

💊The pharma industry faces challenges such as evolving regulatory approvals, acceptance of data from different regions, and incorporating patient perspectives.

🐟Working in a small pharma company offers agility, involvement in various processes, and the opportunity to make a significant impact.

👐Stay open to new perspectives and be willing to modify your opinions based on new information.

🩺Adapt to the evolving regulatory landscape and consider the challenges of generalizing data from different regions.

🏥Recognize the changing role of patients in decision-making and incorporate their perspectives and priorities.

💉Embrace the opportunities for growth and learning in a small company environment.

💊Be bold, clarify your goals, and actively pursue your desired path. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN